DLX3: A Potential Drug Target and Biomarker (G1747)

Target Name: DLX3

NCBI ID: G1747

DLX3

DLX3: A Potential Drug Target and Biomarker

DLX3, short for doublecortin-like peptide 3, is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a 24 amino acid peptide that contains four distinct domains: a N-terminus, a T-terminus, a middle domain, and a C-terminus. The middle domain of DLX3 is rich in conserved acidic and basic residues, which give it a unique structure and a potential role in various cellular processes.

DLX3 has been identified as a potential drug target and biomarker due to its unique structure and the various functions that it is involved in. One of the main reasons for its potential as a drug target is its involvement in the regulation of pain perception and neuroinflammation. DLX3 has been shown to play a role in the regulation of pain perception and has been shown to have neuroprotective properties in various experimental models of pain.

Another potential role for DLX3 as a drug target is its involvement in the regulation of neurogenesis and plasticity. DLX3 has been shown to be involved in the regulation of neuron survival and proliferation in various tissues, including the brain and pancreas. It has also been shown to play a role in the regulation of neurogenesis, which is the process by which new neurons are generated in the brain.

In addition to its potential as a drug target, DLX3 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This is due to its unique structure and the various functions that it is involved in, which make it a valuable tool for the development of new diagnostic tests and therapies.

The discovery and characterization of DLX3 as a potential drug target and biomarker has the potential to have a significant impact on the treatment of various diseases. By targeting the unique structure of DLX3 and its various functions, researchers may be able to develop new treatments for a variety of diseases. This could lead to improved patient outcomes and a greater overall quality of life for those who are suffering from these diseases.

Conclusion

In conclusion, DLX3 is a protein that has the potential to be a drug target and biomarker. Its unique structure and various functions make it an attractive target for researchers to investigate and develop new treatments for various diseases. As more research is conducted on DLX3, it is likely that we will gain a better understanding of its role in various cellular processes and how it can be used to treat a variety of diseases.

Protein Name: Distal-less Homeobox 3

Functions: Likely to play a regulatory role in the development of the ventral forebrain. May play a role in craniofacial patterning and morphogenesis

The "DLX3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLX3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets